The main objective of this aid is the reinforcement of sustainable growth and competitiveness of SMEs and the creation of employment in these, also through productive investments.
The intended result is the creation of new business projects, as well as the expansion, modernization and diversification of pre-existing business initiatives, favoring sustainability, competitiveness and the creation and maintenance of employment.

“To promote technological development, innovation and quality research.”

This operation is financed by the Xunta de Galicia, through the aid granted by the Axencia Galega de Innovación, within the program of aid to the company InnovaPyme in its call 2024.

File no. IN848D-2024-00000045-00

This entity was beneficiary of the FOEXGA Program.
The main objective of this aid is to encourage the implementation of foreign promotion actions that generate competitive advantages. The intended result is the promotion of SMEs and their products and services, increasing the number of export-based companies.

This entity was beneficiary of the Foexga Program.
The main objective of this aid is to encourage the implementation of foreign promotion actions that generate competitive advantages. The intended result is the promotion of SMEs and their products and services, increasing the number of export-based companies.

Grant to finance the hiring of young job seekers to carry out research and innovation initiatives.
[TR349V]

NANOFLUIDETEC: Rapid and automatable detection for SARS-Cov-2 based on PCR, nanotechnology and microfluidics (IN852D 2021/5).

Companies: AMSlab, AMSbiopharma, Bflow and Campus de Lugo de la Universidad de Santiago de Compostela

Project: Rapid and automatable detection for SARS-Cov-2 based on PCR, nanotechnology and microfluidics.

Objective: The overall objective of this project is to develop a point-of-care system for the detection of SARS-CoV-2 based on molecular techniques and integrating nanotechnology and microfluidics with automation and potential connectivity for communication.

The consortium that will carry out this project is formed by 3 Galician SMEs: AMSlab (project leader), AMSbiopharma, BFlow and the Lugo Campus of the University of Santiago de Compostela through the Single Molecule Fluorescence research unit, which will collaborate jointly for its execution.

Thus, NANOFLUIDETEC will make use of the incorporation of essential enabling technologies (EETs) in the research and development of new products with high added value that allow exploring new markets based on the integration of science and technology, especially in the areas of genetics, nanotechnology, microelectronics, photonics, biotechnology, advanced manufacturing and processing, and their treatment and operability through information and communication technologies (ICT).

Total budget: 258.751,04 €

This project is subsidized by the Galician Agency for Innovation (GAIN), financed by ERDF funds and supported by the Xunta de Galicia through the second vice-presidency and Consellería de Economía, Empresa e Innovación. The operation is funded through the CONECTA COVID 2021 program under the REACT-EU axis of the Feder Galicia 2014-2020 operational program, as part of the European Union’s response to the COVID-19 pandemic.

Companies: Hifas da Terra, AMSbiopharma, CIFGA and Tecnologías Plexus.

Objective: The overall objective of this project is the implementation of an accelerated development through prediction based on the integration of chemical and biological data for the discovery of new anti-COVID-19 treatments from fungal and microalgae extracts. The consortium that will carry out this project is formed by 3 SMEs and 1 large Galician company: Hyphae da Terra (leader of the project), AMSbiopharma, CIFGA and Plexus, with the support of the University of Santiago de Compostela as a subcontracted collaborating entity, which will collaborate jointly for its execution. Thus, DIGITAL-BIOCoV will make use of the incorporation of digital technologies in research and development during the discovery phase of bioactive fractions or molecules against SARS-CoV-2 from the integration of bioactivity and chemical data that allow exploring their patentability, value or originality for the pharmaceutical market.

Total budget: 314.486,93 €. This project is subsidized by the Galician Agency for Innovation (GAIN), financed by ERDF funds and supported by the Xunta de Galicia through the second vice-presidency and Consellería de Economía, Empresa e Innovación. The operation is funded through the CONECTA COVID 2021 program under the REACT-EU axis of the Feder Galicia 2014-2020 operational program, as part of the European Union’s response to the COVID-19 pandemic.

The Center for the Development of Industrial Technology (CDTI) has granted AMSbiopharma and Alfredo Iñesta funding for the development of the “Bioentonomy” research project.

Companies: AMSbiopharma and Alfredo Iñesta.

Objectives: Development and formation of new products for use as agricultural inputs from the valorization of insects fed with agro-industrial waste.
Study of the protein and lipid fraction from insect biomass showing interesting biological activity.

Total budget: 642.774 €

This project is part of the call for R&D projects, subsidized by the CDTI, supported by the Ministry of Science, Innovation and Universities and co-financed with European Union Structural Funds (ERDF) within the “Smart Growth Operational Program 2014-2020”.

Business investment AMSbiopharma. Expansion of the capacity of an existing facility (IG253.2019.1.62).

Objective: We seek to increase our portfolio of services for the pharmaceutical sector and for this it is essential to acquire the latest technology equipment to meet the needs of this sector. Due to the requirements in the pharmacopoeia sector, all the equipment must be of exclusive use, which forces us to equip ourselves with new equipment, high technology equipment that will allow us to meet the needs of our customers.

This company was the beneficiary of a grant from IGAPE’s business investment program, which aims to foster the balanced development of the Galician territory and promote the growth and consolidation of SMEs.

Operation co-financed by the European Union.

Galicia ERDF Operational Program 2014-2020.

Achieving a more competitive business fabric.
A way of making Europe.

AMSbiopharma’s digitalization process (IG240.2019.1.54)

Objective: Implementation of Part 11 CRF 21 certification.

Results: It allows us the secularized traceability of the processes of primary data generation, acquisition, processing, reporting, encryption and archiving of digital data obtained with the Sciex 5500 equipment in its application in studies in GLP environment.

This company was the beneficiary of a grant from IGAPE’s “Industry 4.0 digitalization” program, which aims to promote the digital transformation of the company and favor the growth and consolidation of SMEs, improving their financing, technology and access to advanced support services.

Operation co-financed by the European Union.

Galicia ERDF Operational Program 2014-2020.

Achieving a more competitive business fabric.
A way of making Europe.